Latest News


Nancy is grateful for her opportunity at Myrtelle, to help bring innovative therapies to patients with serious, incapacitating, and life-threatening genetic disorders. Nancy joined Myrtelle at its inception in 2021 and brings more than 25 years of experience in drug development. Nancy most recently served as Vice President, Head of Regulatory Affairs at Aruvant Sciences where she led the…

Read more

WAKEFIELD, Mass.–(BUSINESS WIRE)–Myrtelle Inc. (“Myrtelle” or the “Company”), a clinical stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track, Rare Pediatric Disease (RPD), and Orphan Drug designations for its lead clinical-stage gene therapy, rAAV-Olig001-ASPA, for the treatment of…

Read more

Armen Asatryan joined Myrtelle in 2021, shortly after its inception, and has over 20 years of combined experience in pharma/biotech, public health, and clini- cal medicine. Prior to joining the com- pany, Armen held positions of increasing responsibility at Abbott/AbbVie, AveXis/ Novartis, and most recently at AVROBIO, where he was Vice President of Clinical Development…

Read more